Reviewer’s report

Title: MGMT promoter methylation status and MGMT and CD133 expression as prognostic markers in colorectal adenocarcinoma

Version: 1  Date: 12 June 2014

Reviewer: Tamara Tanos

Reviewer’s report:

“MGMT promoter methylation status 1 and MGMT and
2 CD133 expression as prognostic markers in colorectal
3 adenocarcinoma”

The paper analyses the expression of 2 different markers (and promoter methylation status of MGMT) and correlate with OS and DFS.

In this article, authors find several important correlations regarding CD133 and MGMT expression and OS and DFS in CRC patients.

There are few items I believe will help to improve the manuscript:

1-Personally, I would re-compose the title.

2- The authors mention that several patients are already dead. It would be interesting if they can mention how was the level of MGMT expression on these patients.

3-The figures do not have a title that mention what you see there. They should be auto-explanatory. Add please PCR, IHC (and what) and so on.

4-The association between CD133 and MGMT expression that the authors search for are not strong and a bigger cohort of patients may be needed.

Meanwhile, It would be very interesting to observe if MGMT is expressed in CD133 positive cells/areas in good prognosis/OS/DFS patients and low in CD133 cells for bad prognosis/OS/DFS. I would like to know the results of a co-IHC or IF to have a better understanding of the possible importance of MGMT expression in putative stem cells.

All together, the authors add relevant data to the importance of MGMT expression in CRC and its possible role as a disease prognostic marker while CD133 expression and outcome is more confused.

I would suggest the authors to revise what is written here and in a near future add more patient data to conclusively identify if MGMT is a good prognosis marker.

Level of interest: An article of importance in its field
Quality of written English: Acceptable